These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 36297419)

  • 1. Development of Nasal Vaccines and the Associated Challenges.
    Nian X; Zhang J; Huang S; Duan K; Li X; Yang X
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal formulations: promising strategy to deliver vaccines.
    Riese P; Sakthivel P; Trittel S; Guzmán CA
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1619-34. PubMed ID: 24962722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to Develop a Mucosa-Targeting Vaccine against Emerging Infectious Diseases.
    Feng F; Wen Z; Chen J; Yuan Y; Wang C; Sun C
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
    Nagai M; Moriyama M; Ichinohe T
    mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasal and pulmonary vaccine delivery using particulate carriers.
    Jia Y; Krishnan L; Omri A
    Expert Opin Drug Deliv; 2015 Jun; 12(6):993-1008. PubMed ID: 25952104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bridging nanoplatform and vaccine delivery, a landscape of strategy to enhance nasal immunity.
    Teng Z; Meng LY; Yang JK; He Z; Chen XG; Liu Y
    J Control Release; 2022 Nov; 351():456-475. PubMed ID: 36174803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nasal immunization with mannan-decorated mucoadhesive HPMCP microspheres containing ApxIIA toxin induces protective immunity against challenge infection with Actinobacillus pleuropneumoiae in mice.
    Li HS; Shin MK; Singh B; Maharjan S; Park TE; Kang SK; Yoo HS; Hong ZS; Cho CS; Choi YJ
    J Control Release; 2016 Jul; 233():114-25. PubMed ID: 27189136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Trends and Future Challenges of Nanovaccine Delivery
    Dewangan HK; Raghuvanshi A; Shah K
    Curr Drug Targets; 2023; 24(3):261-273. PubMed ID: 36475350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa.
    Tang J; Cai L; Xu C; Sun S; Liu Y; Rosenecker J; Guan S
    Nanomaterials (Basel); 2022 Jan; 12(2):. PubMed ID: 35055244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunity and antiviral vaccinations. Example: the respiratory mucosa].
    Denis F; Hantz S; Alain S
    Antibiotiques (Paris); 2007 May; 9(2):130-138. PubMed ID: 32288532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal Immunization with DOTAP Cationic Liposomes Combined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and Systemic Immune Responses in Mice.
    Tada R; Hidaka A; Iwase N; Takahashi S; Yamakita Y; Iwata T; Muto S; Sato E; Takayama N; Honjo E; Kiyono H; Kunisawa J; Aramaki Y
    PLoS One; 2015; 10(10):e0139785. PubMed ID: 26440657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.
    Kataoka K; Fukuyama Y; Briles DE; Miyake T; Fujihashi K
    Microbiol Immunol; 2017 Jun; 61(6):195-205. PubMed ID: 28463465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines.
    Smith A; Perelman M; Hinchcliffe M
    Hum Vaccin Immunother; 2014; 10(3):797-807. PubMed ID: 24346613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal delivery of nanoparticle-based vaccines.
    Marasini N; Skwarczynski M; Toth I
    Ther Deliv; 2017 Jan; 8(3):151-167. PubMed ID: 28145824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
    Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
    Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of Antigen Adjuvanted with AS04 and Its Deposition in the Upper Respiratory Tract after Intranasal Administration.
    Xu H; Alzhrani RF; Warnken ZN; Thakkar SG; Zeng M; Smyth HDC; Williams RO; Cui Z
    Mol Pharm; 2020 Sep; 17(9):3259-3269. PubMed ID: 32787271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cationic pullulan nanogel as a safe and effective nasal vaccine delivery system for respiratory infectious diseases.
    Nakahashi-Ouchida R; Yuki Y; Kiyono H
    Hum Vaccin Immunother; 2018; 14(9):2189-2193. PubMed ID: 29624474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nasal vaccines].
    Kido H; Mizuno D; Takei T
    Nihon Rinsho; 2008 Oct; 66(10):1881-7. PubMed ID: 18939485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal immunization: a review of strategies and challenges.
    Patel H; Yewale C; Rathi MN; Misra A
    Crit Rev Ther Drug Carrier Syst; 2014; 31(4):273-303. PubMed ID: 25072196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal vaccine as a booster shot: a viable solution to restrict pandemic?
    Meenakshi S; Kumar VU; Dhingra S; Murti K
    Clin Exp Vaccine Res; 2022 May; 11(2):184-192. PubMed ID: 35799869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.